2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L. Catapano, José Luis Zamorano, Ian Graham et al.|European Heart Journal|2016Cited by 3.2k
Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA studyÁngel Lanas, José Luis Zamorano, Jesús Tornero|Annals of the Rheumatic Diseases|2010Cited by 112
2016 ESC/EAS Guidelines for the Management of DyslipidaemiasAlberico L. Catapano, Marie Therese Cooney, Ian Graham et al.|Revista Española de Cardiología (English Edition)|2017Cited by 105
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Alberico L. Catapano, Željko Reiner et al.|European Heart Journal Supplements|2016Cited by 101
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapyCarlos Aguíar, Roberto Ferrari, Eduardo Alegría et al.|Atherosclerosis Supplements|2015Cited by 84